We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Palatability Testing of a New Paediatric Formulation of Valacyclovir (VALID-0)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01682109
Recruitment Status : Completed
First Posted : September 10, 2012
Last Update Posted : December 7, 2020
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by (Responsible Party):
Radboud University Medical Center

Brief Summary:
Palatability testing of a new paediatric formulation of valacyclovir in children 4-12 years of age and at least one of their parents. Children will be included, who received (val)acyclovir prophylaxis in the past, or will probably need it in the future i.e. children with primary immune deficiency or cancer.

Condition or disease Intervention/treatment Phase
Varicella Zoster Virus Infection Herpes Simplex Virus Infection Drug: Valacyclovir Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children
Study Start Date : September 2012
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Shingles

Arm Intervention/treatment
Experimental: new paediatric valacyclovir formulation
Newly developed formulation
Drug: Valacyclovir
Other Name: valacyclovir solution

Active Comparator: reference valacyclovir formulation
Formulation derived from FDA label information
Drug: Valacyclovir
Other Name: valacyclovir solution

Primary Outcome Measures :
  1. Selection of oral solution with best taste [ Time Frame: Day 1 ]
    Patients (children) will assess the taste of 3 different oral solutions. A questionnaire has to be completed to order the palatability of the three formulations.

Secondary Outcome Measures :
  1. Taste assessment [ Time Frame: Day 1 ]
    Children will score the taste of 3 different oral valacyclovir solutions. A 100 mm facial hedonic scale will be employed to indicate the palatability of each formulation.

  2. Predictability of palatability preference of the child by parents. [ Time Frame: Day 1 ]
    To determine whether parents can predict the palatability preference of their child.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is at least 4 years of age.
  • Subject weighs at least 15kg.
  • Subject is capable of performing the taste assessment, according to the investigator's judgement.
  • The child and parent(s) are willing to participate in the taste assessment.
  • Signed informed consent by the legal guardian for participation of the child and if the parent also wants to participate: signed informed consent for their own participation, prior to start of the study.

Exclusion Criteria:

  • Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
  • Presence of any condition that influences taste sensation (such as upper respiratory infection, febrile illness within 3 days before the first dose, mucositis or use of medication that influences taste perception, as described in the label information).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01682109

Layout table for location information
Radboud University Medical Center
Nijmegen, Netherlands
Sponsors and Collaborators
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Layout table for investigator information
Principal Investigator: David Burger Radboud University Medical Center
Publications of Results:
Layout table for additonal information
Responsible Party: Radboud University Medical Center
ClinicalTrials.gov Identifier: NCT01682109    
Other Study ID Numbers: UMCN-AKF 11.05
First Posted: September 10, 2012    Key Record Dates
Last Update Posted: December 7, 2020
Last Verified: December 2020
Keywords provided by Radboud University Medical Center:
herpes zoster
herpes simplex
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Virus Diseases
Herpes Simplex
Herpes Zoster
Varicella Zoster Virus Infection
Disease Attributes
Pathologic Processes
Herpesviridae Infections
DNA Virus Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Antiviral Agents
Anti-Infective Agents